Neuraxpharm steps into the Digital Health market with a wearable device developed by mjn-neuro that provides an early warning of epileptic seizures

The CNS specialist Neuraxpharm has signed a commercialisation agreement with mjn-neuro with exclusivity in Europe Düsseldorf and Barcelona / Blanes, Girona, October 25, 2022 - Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), and mjn-neuro, a start-up that designs, manufactures and markets medical devices, today announce the signing of a commercialisation agreement for mjn-SERAS, a wearable medical device that aims to predict the risk of having an epileptic seizure.With this agreement, Neuraxpharm increases